Señales en vivo de KPTI | Maximiza tus Ganancias con Getagraph.com

COMPRAR 105715 min ago

@ $1.418

Emitido: 14 feb 2024 @ 15:43

Retorno: -25.25%

Señal anterior: feb 13 - 12:41

Señal anterior: Vender

Retorno: 12.54 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Stats
Volumen de hoy	652 441
Volumen promedio	1.79M
Capitalización de mercado	123.45M
EPS	$0 ( 2024-02-29 )
Próxima fecha de ganancias	( $-0.330 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.850
ATR14	$0.00200 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Rangwala Reshma	Sell	6 789	Common Stock
2024-04-04	Paulson Richard A.	Sell	3 563	Common Stock
2024-03-05	Paulson Richard A.	Sell	3 573	Common Stock
2024-02-29	Rangwala Reshma	Sell	15 667	Common
2024-03-01	Rangwala Reshma	Sell	5 969	Common

INSIDER POWER
69.84
Last 99 transactions
Buy: 2 857 011 \| Sell: 554 783

Volumen Correlación

Largo: -0.29 (neutral)

Corto: -0.93 (very strong negative)

Signal:(25.667) Possible Trading Opportunity Present (swing)

Karyopharm Therapeutics Correlación

10 Correlaciones Más Positivas
RMRM	0.914
GAINL	0.87

10 Correlaciones Más Negativas
BRAG	-0.833
EM	-0.806
AVTE	-0.804
ARCE	-0.803

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Karyopharm Therapeutics Correlación - Moneda/Commodity

0.00
( neutral )

0.04
( neutral )

Karyopharm Therapeutics Finanzas

Annual	2023
Ingresos:	$146.03M
Beneficio Bruto:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2023
Ingresos:	$146.03M
Beneficio Bruto:	$140.56M (96.25 %)
EPS:	$-1.250

FY	2022
Ingresos:	$157.07M
Beneficio Bruto:	$151.86M (96.68 %)
EPS:	$-2.02

FY	2021
Ingresos:	$209.82M
Beneficio Bruto:	$206.42M (98.38 %)
EPS:	$-1.650

Financial Reports:

No articles found.

Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Actualizaciones en tiempo real para Karyopharm Therapeutics [KPTI]

Upcoming Earnings Alert